The therapeutic application of this preparation is used in areas where short-term symptom management is appropriate for various conditions presenting with systemic or localized discomfort. The medicine is commonly used, and its role is relevant when supportive symptom management is appropriate. It is used across therapeutic domains involving localized surface pain and soreness, such as discomfort arising from minor cuts, abrasions, scrapes, sunburns, or minor burns, as well as intense, localized itching (pruritus) from insect bites and minor skin irritations.

The preparation contributes to symptomatic relief that helps patients cope more steadily with symptom fluctuations, which helps ease the overall symptom load following acute skin trauma or during episodes of heightened discomfort. It is also relevant in clinical settings marked by heightened patient distress associated with anorectal pain, burning, and pruritus, typically seen in conditions like hemorrhoids or anal fissures. In these situations, short-term symptomatic assistance is appropriate, contributing to easing the overall symptom load.

“The primary goal of this preparation is to support the patient during difficult episodes by easing distress caused by localized pain and persistent itching.”

---

Quick Fact: Support for Localized Discomfort

Quick Fact: Support for Localized Pain and Pruritus. The medicine is commonly used to help with symptoms related to heightened physiological activity and to manage manifestations that interfere with daily comfort.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Regenecare?

The eligibility for Regenecare is strictly defined by regulatory documents that identify populations at risk of systemic toxicity from topical exposure to this amide-type local anesthetic.

The medicine is contraindicated in patients with a history of hypersensitivity to lidocaine or any other amide-type local anesthetic. Use is also prohibited for patients with severe shock or heart block. Furthermore, the medicine must not be used on severely traumatized or infected mucosa due to the high risk of rapid systemic absorption.

Restricted use is documented for several populations. Caution is required for patients with severe hepatic disease because the liver metabolizes the active ingredient, potentially leading to toxic plasma concentrations. Patients with renal impairment also require caution due to the risk of metabolite accumulation.

Age Group	Eligibility Status (Regulatory Labeling)
Adults	Generally approved for use.
Children < 2 Years	Use requires caution; safety and efficacy are not established.
Elderly/Debilitated	Requires caution and reduced doses.

For Pregnancy, the medicine is classified as Category B and should be used only if clearly needed. Caution is required for nursing mothers as lidocaine is excreted into human milk.

Interactions with other medicines and products

Regenecare’s interaction profile is officially defined by its metabolism through hepatic enzymes and its potential for additive pharmacodynamic effects. The following information is based strictly on regulatory documents, such as FDA Prescribing Information.

Property	Value
Medicinal product categories with documented interactions	Local anesthetics; Methemoglobinemia-inducing agents; CYP450 3A4 and 1A2 inhibitors.
Specific interacting medicines (if explicitly listed)	Itraconazole, Erythromycin, Fluvoxamine, Ciprofloxacin (CYP enzyme inhibitors).
Mechanistic basis of interactions	Pharmacokinetic (Inhibition of CYP3A4/1A2 leading to increased plasma concentration); Pharmacodynamic (Additive toxic effects).

Official Interaction Statements

• Co-administration with potent or moderate CYP450 3A4 and CYP450 1A2 inhibitors (e.g., Itraconazole or Fluvoxamine) is noted to increase lidocaine plasma concentrations and systemic exposure, a documented pharmacokinetic interaction.
• The toxic effects of other local anesthetics are additive when co-administered, requiring monitoring for combined neurologic and cardiovascular effects.
• Concurrent use of other methemoglobinemia-inducing agents (such as Nitrites or Sulfonamides) significantly increases the documented risk of methemoglobinemia.
• Timing-based restriction: When the product is applied to the mouth or throat, food and chewing gum must not be consumed for 60 minutes post-use, a procedural constraint against impaired swallowing.
• Population-specific caution: Patients with severe hepatic disease are noted to be at a greater risk of toxic blood concentrations, a note relevant when considering interactions that further reduce clearance.

How Regenecare Works

Targeted Blockade of Voltage-Gated Sodium Channels

The core mechanism of Regenecare involves the drug acting as a competitive inhibitor at the Voltage-Gated Sodium Channels ( NaV) found on peripheral nerve membranes. By physically blocking the inner pore of the channel, the drug prevents the necessary influx of sodium ions ( Na^+), thereby stabilizing the membrane and halting the electrical activity required for signal transmission.

---

Reversible Interruption of Nerve Signal Transmission

The molecular blockade translates directly into an interruption of the Nociceptive Signaling Pathway at the periphery. This action prevents the nerve cell from generating an electrical impulse (action potential), which results in a localized, reversible cessation of afferent signal conduction from the peripheral nerves to the central nervous system. The physiological consequence of this targeted inhibition is a temporary state characterized by abolished sensory nerve excitability.

---

Mechanism Constraints by Tissue Environment

The effectiveness of the mechanism is constrained by the local chemical environment, as the drug must penetrate the nerve sheath to act internally. In situations involving tissue acidosis (such as infection or inflammation), the drug's ability to cross the membrane is impaired, consequently reducing the degree of sodium channel blockade and limiting the resulting physiological effect.

How Regenecare is used

Regenecare is intended for topical administration, applying the preparation directly to the dermal surface or accessible mucous membranes, such as the urethra or anorectal area. The application route is determined by the specific formulation used, which includes ointments, gels, or jellies.

The use of Regenecare is governed by maximum dosage limits. For the 5% ointment, the maximum single dose applied should not exceed 5 grams, and the absolute total dose administered in any single 24-hour period must not exceed 20 grams. For specialized formulations like the 2% jelly, the total administered dose is limited to 600 milligrams of lidocaine in any 12-hour period, based on specific procedural requirements.

The medicine is used on an as-needed basis for short-term symptomatic use, typically applied three or four times daily. When administering the medicine, the lowest dosage required for effective anesthesia must be used. A critical administration constraint is the requirement to account for the total amount of lidocaine delivered from all concomitant lidocaine-containing products to avoid exceeding established safety thresholds.

Dosage adjustments are mandated for specific patient groups. For pediatric patients, the maximum single dose must not exceed 4.5 milligrams per kilogram of body weight. Dosages must also be reduced for older or debilitated adults, commensurate with their physical condition.

Research Evidence / Overview of Studies

---

Phase 3 Trials and Primary Endpoints

Research has explored whether the drug may be associated with reduced inflammation and alleviation of pain, particularly in the context of rheumatological conditions like mild-to-moderate arthritis. These large-scale trials primarily focused on two main patient-reported outcomes: pain scores (measured via the Visual Analog Scale) and physical function (measured via the Health Assessment Questionnaire).

Studies evaluated whether the drug was associated with changes in joint swelling and stiffness in the participant cohorts. The primary research designs included randomized, double-blind, placebo-controlled trials to establish robust evidence, with study protocols generally including specific administration schedules.

Key Study Findings

One key study reported a measurable decrease in symptom severity for a majority of participants compared to placebo; however, evidence remains limited regarding its comparative profile to existing treatments.

• Pain Score Change: Findings indicated a measurable change in pain scores compared to the placebo group across many cohorts examined. The duration of this observation was limited to the trial length, typically 12 weeks.
• Impact on Function: Changes in physical function scores were also reported in a number of participants receiving the treatment versus those receiving placebo.

Long-term endpoints for safety and participant response were points of focus in several studies, which also examined whether the drug influenced the rate of disease change. Follow-up studies investigated whether observations held beyond the initial trial period, but the data collection timeframe remains restricted.

Tolerability and Safety Profile Overview

Research protocols typically excluded participants with pre-existing liver conditions, as adverse events in this population have been noted. The adverse events most frequently reported in the studies included gastrointestinal discomfort and headache.

The combined data suggests that this treatment option has been widely explored in clinical research. Continued monitoring and investigation into the long-term profile of the drug remains underway.

Key Studies & References Label: REGENECARE HA- lidocaine hcl gel (DailyMed - FDA)

Common questions about Regenecare (FAQ)

---

Q: How quickly can I expect to notice any effects from Regenecare?

A: Information for topical lidocaine products suggests that the localized numbing effect can typically begin within 30 to 60 minutes after the application is completed. The precise time frame is influenced by the specific formulation being used and the area where it is applied.

---

Q: Can Regenecare affect laboratory test results?

A: Regulatory documents mention that the use of lidocaine, particularly the injectable form, may increase creatine phosphokinase (CPK) levels. The relevance of this finding depends on the context of the testing performed, as CPK levels are sometimes evaluated in relation to heart function.

---

Q: If I miss a dose of Regenecare, what does the official label say I should do?

A: Official patient information describes that if a dose is missed on a regular schedule, application is recommended as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the regulatory instruction indicates skipping the missed dose and continuing with the regular schedule. The label cautions against applying double the dose to compensate for a missed one.

---

Q: What is the half-life of Regenecare according to drug regulatory documents?

A: The half-life refers to the time it takes for the drug concentration in the body to reduce by half. The official elimination half-life of lidocaine following intravenous injection is generally reported to be 1.5 to 2.0 hours. It is noted that this duration may be longer in patients who have liver dysfunction.

---

Q: How is the safety of Regenecare monitored after it has been approved?

A: Official safety monitoring by regulatory agencies is an ongoing process that occurs after the medicine has been approved. This monitoring includes the continual collection of adverse event reports submitted by healthcare providers and users, as well as the regular submission of Periodic Safety Update Reports (PSURs) by the manufacturer.

---

Q: Does Regenecare require a prescription, or is it available over the counter?

A: Topical lidocaine products are generally available in both prescription and over-the-counter (OTC) strengths and formulations. The required status (prescription vs. OTC) is determined by the specific concentration and intended use of the particular Regenecare product.

---

Q: Does Regenecare interact with alcohol?

A: Official patient information for similar lidocaine products advises that concurrent consumption of alcohol with the medication is not recommended. This is because alcohol may cause your blood pressure to drop, which could potentially lead to side effects such as dizziness or fainting.

---

Q: Can Regenecare affect my sleep?

A: Regulatory documents indicate that the use of lidocaine is associated with Central Nervous System (CNS) effects. These effects include drowsiness, sedation, and confusion, all of which may affect a person's sleep pattern or general alertness.

---

Q: Is Regenecare a drug that requires regular monitoring?

A: Routine, scheduled monitoring is generally not required for all users, but monitoring of circulation and respiration may be necessary for specific patient groups. This includes patients at higher risk of systemic toxicity—such as those with severe liver disease—or those using other local anesthetics simultaneously.

---

Q: Is it safe to drive or operate machinery while using Regenecare?

A: Official patient information for lidocaine products advises that the medication may affect the ability to safely drive or operate heavy machinery. Official patient information indicates that if the ability to safely drive or operate heavy machinery is affected, these activities should be avoided until full function returns.

---

Q: What does 'contraindication' mean in the context of Regenecare?

A: A contraindication is a term used in regulatory documents to identify a specific condition or factor that prevents a medical treatment from being used. If a person has a contraindication, it is a reason to withhold the drug because using it under that condition could lead to an undesirable outcome.

---

Q: Are there specific signs of an overdose with Regenecare?

A: Official safety information for the active ingredient describes signs of toxicity, which happen when blood levels become too high. Early indications include dizziness, blurred vision, shakiness, confusion, and drowsiness. In more serious cases, these elevated blood levels can lead to severe systemic reactions such as convulsions or cardiac arrest.

How to Store and Dispose of Regenecare (Lidocaine HCl Gel)

Official regulatory guidelines strictly define the storage environment and handling of Regenecare to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Must be stored at room temperature.
Protection	Avoid freezing and excessive heat.
Child Safety	Mandatory to keep the product out of reach of children.

Disposal Instructions

Official labeling does not provide specific disposal instructions for the gel. Unused or expired product should be discarded according to general governmental recommendations. This includes utilizing drug take-back programs or disposing of the medicine in the household trash after mixing it with an undesirable substance.